GLP-1 supply chain signals building — manufacturing capacity constraints a known risk. No acute OSINT disruption signal. Monitor.
| Ticker | Company | Score | Gap | Signal Δ | Action |
|---|---|---|---|---|---|
| TAK | Takeda Pharmaceutical Company Limited | 37 | +10% | ↓0% | NEUTRAL |
| NVO | Novo Nordisk A/S | 37 | 0% | ↓0% | NEUTRAL |
| AZN | AstraZeneca PLC | 37 | +11% | ↓0% | EARLY |
| SNY | Sanofi | 37 | +14% | ↓0% | EARLY |
| REGN | Regeneron Pharmaceuticals Inc. | 37 | -16% | ↓0% | AVOID |
| GSK | GSK plc | 37 | +8% | ↓0% | NEUTRAL |
| LLY | Eli Lilly and Company | 37 | +24% | ↓0% | EARLY |
Estimates · Yahoo Finance · Not audited figures